Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Rituximab].

Rumiko Okamoto1, Yoshiharu Maeda, Tsuneo Sasaki

  • 1Dept. of Chemotherapy, Tokyo Metropolitan Komagome Hospital.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|August 27, 2003
PubMed
Summary

Rituximab, a monoclonal antibody targeting CD20, improves outcomes for non-Hodgkin's lymphoma (NHL). It enhances chemotherapy effectiveness in aggressive NHL and shows promise in indolent forms, offering new hope for patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effects of online facial muscle training with resonance vocalization on mental health in postpartum women: A single-arm pilot study.

Women's health (London, England)·2024
Same author

[In Commemoration of the 50th Anniversary of Gan To Kagaku Ryoho].

Gan to kagaku ryoho. Cancer & chemotherapy·2023
Same author

Effects of Facial Muscles Exercise on Mental Health: A Systematic Review.

International journal of environmental research and public health·2021
Same author

Design and Optimization of Scored Tablets with Concave Surface and Application of Bayesian Estimation for Solving Scaleup Problem.

Chemical & pharmaceutical bulletin·2021
Same author

A comparison on the percentage of polymerase chain reaction positivity for SARS-CoV-2 between Public Health Center referrals and direct walk-in patients: A single center retrospective analysis in Tokyo.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2021
Same author

Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma.

Journal of hepatology·2020

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Context:

  • Non-Hodgkin's lymphoma (NHL) treatment remains challenging, with limited cures for indolent forms and only moderate success with standard CHOP chemotherapy for aggressive NHL.
  • Rituximab, a chimeric monoclonal antibody, targets the CD20 antigen on B-cells, sparing stem cells and plasma cells.
  • Existing therapies like CHOP chemotherapy have limitations in efficacy and cure rates for various NHL subtypes.

Purpose:

  • To evaluate the efficacy and safety of rituximab in treating different types of non-Hodgkin's lymphoma.
  • To determine rituximab's role as a standalone therapy or in combination with chemotherapy for NHL.
  • To explore novel therapeutic strategies involving monoclonal antibodies for lymphoma treatment.

Summary:

  • Rituximab demonstrates significant efficacy in indolent NHL, showing useful response rates in first-line and relapsed settings.
  • In aggressive NHL, particularly diffuse large B-cell lymphoma, adding rituximab to CHOP chemotherapy improves disease-free and overall survival, especially in elderly patients.
  • Ongoing research investigates rituximab in combination regimens, maintenance therapy for minimal residual disease, and autologous transplantation, alongside newer antibody-based therapies.

Impact:

  • Rituximab offers a well-tolerated treatment option with minimal cross-resistance to conventional agents.
  • The integration of rituximab into NHL treatment protocols has improved patient survival and quality of life.
  • Further research into antibody-based therapies promises to advance lymphoma treatment paradigms.

Related Experiment Videos